Haemonetics Cp: (NYSE: HAE)
$41.14
1.25 (3.13%)
Volume 596,412
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 39.92 - 41.14 |
| 52wk Low - High | 32.69 - 44.44 |
| Previous Close | 39.89 |
| Avg. Volume | 393,572 |
| Industry | MED PRODUCTS |
| Market Cap | 2.12 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.42 |
| PE (Forward) | 19.31 |
| Current Year Est. | 2.13 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
175 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 19.31 |
| PEG Ratio | 1.57 |
| Current Year Est. | 2.13 |
| Current Quarter Estimate | 0.42 |
| Most Accurate Estimate | 0.42 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | 1.71 |
| Expected Earnings Growth | 12.33% |
Company Description
Haemonetics is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collections and plasma collections. The majority of their business is outside the US.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (03/2014) |
Next Year (03/2015) |
|
|---|---|---|---|---|
| Average Estimate | 0.42 | 0.51 | 2.13 | 2.60 |
| Number of Estimates | 4 | 4 | 4 | 2 |
| Low Estimate | 0.36 | 0.45 | 1.89 | 2.55 |
| High Estimate | 0.47 | 0.58 | 2.34 | NA |
| Year Ago EPS | 0.28 | 0.45 | 1.71 | 2.13 |
| EPS Growth | 52.73% | 14.44% | 24.56% | 22.07% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| HAEMONETICS CP | HAE | 41.14 | |
|
| CONCEPTUS INC | CPTS | 30.92 | |
|
| ATRICURE INC | ATRC | 9.07 | |
|
| CYTOSORBENTS CP | CTSO | 0.12 | |
|
| INVIVO THERAPT | NVIV | 2.89 | |
|
| TRANS1 INC | TSON | 1.70 | |
|
| ABAXIS INC | ABAX | 45.35 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| ALERE INC | ALR | 26.30 | |
|
| BAXTER INTL | BAX | 72.94 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
HAE Beats on Earnings, Revs in Line
May 03, 2013
Haemonetics Closes Hemerus Acquisition
May 02, 2013
Covidien Likely to Beat Earnings?
Apr 24, 2013
Will Stryker Miss Earnings this Quarter?
Apr 23, 2013
Will CR Bard Miss Earnings this Quarter?
Apr 22, 2013
Haemonetics Back to Neutral
Apr 15, 2013
Palls New Center of Excellence
Apr 05, 2013
PLL Expands into Research
Mar 06, 2013
Financials
| EPS TTM | 1.71 |
| Sales | 892 |
| Net Income | 39 |
| Price/Earnings | 24.13 |
| Price/Book | 2.76 |
| Price/Cash Flow | 16.12 |
| Price/Sales | 2.38 |
News
Haemonetics Makes a Move: Up 1.5% - Financial News Network Online - Market Movers
May 16, 2013
Quidel Ranks the Highest in Terms of EBITDA Growth in the Health Care Supplies Industry (QDEL, HAE, RTIX) - Financial News Network Online - News Corner
May 14, 2013
Haemonetics reports lower Q4 net income, provides outlook for fiscal 2014 - Datamonitor
May 10, 2013
Haemonetics Fulfills the Promise: Up 1.8% Since Last Week's Upgrade - Financial News Network Online - News Corner
May 9, 2013
Analyst Rating In Review: Haemonetics Sold Off 2.2% Since Upgraded 7 Days Ago (HAE) - Financial News Network Online - News Corner
May 3, 2013
Upgrade Alert for Haemonetics (HAE) - Comtex Smartrend(R)
May 3, 2013
Haemonetics Corporation acquires Hemerus Medical LLC for USD24m - M2
May 2, 2013
Haemonetics CorporationCorporate Event Announcement Notice - Wall Street Horizon
May 2, 2013
Broker Recommendations
| Current ABR | 2.20 |
| ABR (Last Week) | 2.20 |
| # of recs in ABR | 5 |
| Average Target Price | 44.00 |
| Industry Rank by ABR | 175 out of 265 |
| Rank in Industry | 6 out of 72 |
